JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
JAK Inhibition with Ruxolitinib versus Best Available Therapyfor Myelofibrosis / C. Harrison, J.J. Kiladjian, H.K. Al-Ali, H.Gisslinger, R. Waltzman, V. Stalbovskaya, M. McQuitty, D. S. Hunter, R. Levy, L. Knoops, F. Cervantes, A.M. Vannucchi, T. Barbui, G. Barosi. - In: THE NEW ENGLAND JOURNAL OF MEDICINE. - ISSN 0028-4793. - STAMPA. - 366(9):(2012), pp. 787-798. [10.1056/NEJMoa1110556]
JAK Inhibition with Ruxolitinib versus Best Available Therapyfor Myelofibrosis
VANNUCCHI, ALESSANDRO MARIA;
2012
Abstract
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
NEJM_12030106.pdf
accesso aperto
Tipologia:
Versione finale referata (Postprint, Accepted manuscript)
Licenza:
Open Access
Dimensione
591.35 kB
Formato
Adobe PDF
|
591.35 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
